1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6633F4714E8865BAB65257945002E38BC
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/oncology-market-education-engaging-key-opinion-leaders?opendocument
18
19opendocument
2018.206.194.83
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Market Entry and Oncology

Oncology Market Education: Engaging Key Opinion Leaders

ID: 5168


Features:

8 Info Graphics

17 Data Graphics

200 Metrics

11 Narratives

2 Best Practices


Pages/Slides: 40


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Oncology Market Education: Engaging Key Opinion Leaders"

STUDY OVERVIEW

Educating the marketplace about a new product is part of every new product launch. For oncology products, Key Opinion Leaders (KOLs) are among the most important education targets as they can help shape treatment practices. What's not clear is what are the best tactics, timing and activities for engaging and educating thought leaders about new oncology therapies.

Best Practices, LLC conducted this research to identify the best timing for informing KOLS as well as the most effective activities for engaging thought leaders. The study also discusses the identification of KOL segments that align with the new therapy, the role of advisory boards and managing clinical trials to engage thought leaders. Oncology launch leaders can use this study to compare their KOL engagement and education tactics and strategies with those used by industry leaders.

KEY TOPICS

    • Developing integrated continuous thought-leader strategies
    • Identifying and engaging physicians who shape therapeutic direction, and guidelines
    • Cultivating and maintaining relationships with Key Opinion Leaders who shape the market to enhance thought leader relationships and value management
    • Managing clinical trials to win highly regarded investigators and thought leaders
    • Utilizing investigator-initiated studies to engage key investigators in developing the product’s full potential

SAMPLE KEY METRICS
  • Development phase to start each activity for educating thought leaders
  • Top three most important activities in thought leader education category
  • Estimated number of thought leaders planned to target during each phase III pre-launch period for inline and emerging products
  • Estimated number of field based medical science liaisons assigned during each year of the phase III pre-launch period to a product in a new therapeutic area
  • Development phase to start relationship development with various thought leader segment
  • Frequency of face-to-face calls by field based medical specialist or liaisons to grow relationship with thought leaders
  • Role of each type of thought leader
  • Importance rating of different tactics in building credibility for company when entering a new therapeutic area
  • Factors having greatest positive impact in building credibility for company when entering a new therapeutic area
  • Important factors leading an investor to choose a company’s study over another study
  • Stages during which investigator initiated studies were conducted

SAMPLE KEY FINDING
  • Winning and Managing Thought-Leader Relationships: Thought Leaders are cornerstones of success. Thought Leader insights range broadly from starting early to develop critical relationships, seeding Medical Science Liaison (MSL) resources early, committing to the therapeutic area to win influential investigators, employing segmentation to identify and manage top thought leaders, investigators and Key Opinion Leaders (KOLs), and managing the coordination of national and regional thought leaders across the value chain throughout development.


METHODOLOGY

The benchmark class includes 34 executives and managers at 26 leading pharmaceutical, biotech and medical device companies. In addition, deep-dive executive interviews were conducted with selected participants to provide qualitative insights and emerging trends.


Industries Profiled:
Pharmaceutical; Biotech; Health Care; Service; Medical Device; Technology; Manufacturing; Consumer Products; Diagnostic; Chemical


Companies Profiled:
GlaxoSmithKline; ARIAD; Pfizer; Integrated Communications Corp.; Novartis; Genitope Corporation; NeoVista; Inc.; Amgen; Novo Nordisk; Johnson & Johnson; AstraZeneca; Roche; Lilly; Bayer; Human Genome Sciences; Boehringer Ingelheim; Nobel Biocare; Abbott; Solvay Pharmaceuticals; Genentech; Sanofi-aventis; Smith & Nephew; Amylin; Janssen Cilag Pharmaceutical; Dr Reddy's Laboratories; Spectrum Pharmaceutical

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.